Because the above data is molecular response collected in-vitro, though very promising, it may not be applicable clinically as yet. There are actually a number of agents being evaluated clinically (ITX5061, silibinin, anti-clonal antibodies, triple tx as well as riba/IV INF) to prevent infection post-transplant... definitely a good in-depth topic for your next visit to the TP center.~eur
Thanks Eureka. You make a good point. It will take perhaps years, if something can be learned for these catechins at best, and I will need transplant with a year. So...whatever is available medically this year is really my only options.
The other grip I have is... I am not wild about anything to do with green tea even if it is just isolated catechins. EGCG and its derivatives, epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC). Green tea tastes flat and like dirty grass to me. This will mean more anti-nausea meds. Just what we need. (!) It would be so much more "user-friendly" if they could make a antiviral in the form of a root beer or cherry popsicle. One less pill to take. I would be the first in line!
Seriously I have only been following the the 2 and 3 drug hepatitis C treatments. And will ask my doctor if their is a possibly of trying something to prevent reinfection of my donor liver.
Another new and very interesting possibility for future TP recipients ...
Entry Point for Hepatitis C Infection Identified:
January 24, 2012 -- A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.
Previous studies showed that cholesterol was somehow involved in HCV infection. The UIC researchers suspected that a receptor called NPC1L1, known to help maintain cholesterol balance might also be transporting the virus into the cell.
The FDA-approved drug ezetimibe (sold under the trade-name Zetia) is readily available and perfectly targeted to the receptor, Sainz said, so the researchers had an ideal method for testing NPC1L1's involvement in HCV infection.
The researchers showed that ezetimibe inhibited HCV infection in cell culture and in mice transplanted with human liver cells. And, unlike any currently available drugs, ezetimibe was able to inhibit infection by all six types of HCV.
While current drugs are highly toxic and often cannot be tolerated by transplant patients taking immunosuppressant drugs, ezetimibe is quite safe and has been used long-term without harm by people to control their cholesterol, Uprichard said. Because it prevents entry of the virus into cells, ezetimibe may help protect the new liver from infection.
Copyright 1994-2016MedHelp International.All rights reserved. MedHelp is a division of Aptus Health.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.